Statistik Asas
| LEI | 529900YOD61G7ECPV281 |
| CIK | 1607962 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Lifeward Ltd.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| August 25, 2025 |
LIFEWARD LTD. 2025 INCENTIVE COMPENSATION PLAN Notice of Option Grant Exhibit 99.3 LIFEWARD LTD. 2025 INCENTIVE COMPENSATION PLAN Notice of Option Grant Participant: [•] Company: Lifeward Ltd. Notice: You have been granted the following Non-Qualified Stock Option to purchase Shares in accordance with the terms of the Plan, this Notice of Option Grant and the Non-Qualified Stock Option Award Agreement attached hereto as Schedule A (this Notice of Option Grant, togeth |
|
| August 25, 2025 |
LIFEWARD LTD. 2025 INCENTIVE COMPENSATION PLAN Notice of Option Grant Exhibit 99.2 LIFEWARD LTD. 2025 INCENTIVE COMPENSATION PLAN Notice of Option Grant Participant: [•] Company: Lifeward Ltd. Notice: You have been granted the following Incentive Stock Option to purchase Shares in accordance with the terms of the Plan, this Notice of Option Grant and the Incentive Stock Option Award Agreement attached hereto as Schedule A (this Notice of Option Grant, together with |
|
| August 25, 2025 |
LIFEWARD LTD. 2025 INCENTIVE COMPENSATION PLAN Notice of Restricted Share Unit Grant Exhibit 99.5 LIFEWARD LTD. 2025 INCENTIVE COMPENSATION PLAN Notice of Restricted Share Unit Grant Participant: Company: Lifeward Ltd. Notice: You have been granted the following Restricted Share Units in accordance with the terms of the Plan, this Notice of Restricted Share Unit Grant and the Restricted Share Unit Award Agreement attached hereto as Attachment A (this Notice of Restricted Share Uni |
|
| August 25, 2025 |
As filed with the Securities and Exchange Commission on August 25, 2025 As filed with the Securities and Exchange Commission on August 25, 2025 Registration No. |
|
| August 25, 2025 |
Exhibit 99.6 LIFEWARD LTD. 2025 INCENTIVE COMPENSATION PLAN Notice of Restricted Share Unit Grant - According to 102 Capital Gains Track (with Trustee) Participant: Company: Lifeward Ltd. Notice: You have been granted the following Restricted Share Units (“RSUs”) in accordance with the terms of the 2025 Incentive Compensation Plan and the Sub-Plan for Participants in Israel (the “Sub-Plan” and, to |
|
| August 25, 2025 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-8 LIFEWARD LTD. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Ordinary Shares, par va |
|
| August 25, 2025 |
Exhibit 4.1 DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a description of the ordinary shares, par value NIS 1.75 per share, of Lifeward Ltd. (the “Company,” “we” or “us”) registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). This description is a summary and is qu |
|
| August 25, 2025 |
As filed with the Securities and Exchange Commission on August 25, 2025 As filed with the Securities and Exchange Commission on August 25, 2025 Registration No. |
|
| August 25, 2025 |
As filed with the Securities and Exchange Commission on August 25, 2025 As filed with the Securities and Exchange Commission on August 25, 2025 Registration No. |
|
| August 25, 2025 |
As filed with the Securities and Exchange Commission on August 25, 2025 As filed with the Securities and Exchange Commission on August 25, 2025 Registration No. |
|
| August 25, 2025 |
Exhibit 99.4 LIFEWARD LTD. 2025 INCENTIVE COMPENSATION PLAN Notice of Option Grant - According to 102 Capital Gains Track (with Trustee) Participant: [•] Company: Lifeward Ltd. Notice: You have been granted the following Stock Option to purchase Ordinary Shares of the Company, par value NIS 1.75 per share, in accordance with the terms of the 2025 Incentive Compensation Plan and the Sub-Plan for Pa |
|
| August 25, 2025 |
As filed with the Securities and Exchange Commission on August 25, 2025 As filed with the Securities and Exchange Commission on August 25, 2025 Registration No. |
|
| August 25, 2025 |
As filed with the Securities and Exchange Commission on August 25, 2025 As filed with the Securities and Exchange Commission on August 25, 2025 Registration No. |
|
| August 14, 2025 |
Seventh Amended and Restated Articles of Association of the Company. Exhibit 3.1 THE ISRAELI COMPANIES LAW A COMPANY LIMITED BY SHARES SEVENTH AMENDED AND RESTATED ARTICLES OF ASSOCIATION OF Lifeward Ltd. GENERAL PROVISIONS 1. Definitions a) In these Articles the following terms shall bear the meaning ascribed to them below: “Alternate Director” is defined in Article 41. “Annual General Meeting” shall have the meaning assigned to such term in the Companies Law. The |
|
| August 14, 2025 |
Exhibit 10.3 LIFEWARD LTD. NOTICE OF NONQUALIFIED STOCK OPTION GRANT Participant: [•] Company: Lifeward Ltd. (the “Company”). Notice: You have been granted the following Nonqualified Stock Option to purchase Ordinary Shares, par value NIS 1.75 per share. This is an inducement grant, as described in NASDAQ Listing Rule 5635(c)(4), and shall be governed by this Notice of Nonqualified Stock Option Gr |
|
| August 14, 2025 |
Exhibit 99.1 Lifeward Ltd. Reports Second Quarter 2025 Financial Results Achieves record number of ReWalk systems placed for Medicare beneficiaries since fee schedule established Third consecutive quarter of U.S. ReWalk pipeline growth with over 130 qualified leads in process Appoints new CEO and CFO to spearhead strategic change and accelerate growth MARLBOROUGH, MA, and YOKNEAM ILLIT, Israel, Au |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36612 Lifeward Ltd. (Exact |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 Lifeward Ltd. (Exact Name of Registrant as Specified in its Charter) Israel 001-36612 Not Applicable (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| August 13, 2025 |
Lifeward Names Almog Adar as New CFO, Strengthening Executive Leadership Exhibit 99.1 Lifeward Names Almog Adar as New CFO, Strengthening Executive Leadership MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, August 13, 2025 (GLOBE NEWSWIRE) - Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that Almog Adar, who previously |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 Lifeward Ltd. (Exact Name of Registrant as Specified in its Charter) Israel 001-36612 Not Applicable (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 Lifeward Ltd. (Exact Name of Registrant as Specified in its Charter) Israel 001-36612 Not Applicable (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2025 Lifeward Ltd. (Exact Name of Registrant as Specified in its Charter) Israel 001-36612 Not Applicable (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| June 26, 2025 |
Exhibit 4.1 ORDINARY SHARE PURCHASE WARRANT LIFEWARD LTD. Warrant Shares: [] Issue Date: [], 2025 Initial Exercise Date: [], 2025 THIS ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date se |
|
| June 26, 2025 |
Filed Pursuant to Rule 424(b)(4) Registration No. 333-288172 PROSPECTUS 4,000,000 Ordinary Shares 4,000,000 Warrants to Purchase Up to 4,000,000 Ordinary Shares 240,000 Placement Agent Warrants to Purchase Up to 240,000 Ordinary Shares 4,240,000 Ordinary Shares Issuable Upon Exercise of the Warrants and Placement Agent Warrants We are offering 4,000,000 ordinary shares, par value NIS 1.75 per shar |
|
| June 26, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2025 Lifeward Ltd. (Exact Name of Registrant as Specified in its Charter) Israel 001-36612 Not Applicable (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| June 26, 2025 |
Form of Securities Purchase Agreement. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 25, 2025, between Lifeward Ltd., a corporation organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject |
|
| June 26, 2025 |
Form of Placement Agent Warrant. Exhibit 4.2 PLACEMENT AGENT ORDINARY SHARE PURCHASE WARRANT LIFEWARD LTD. Warrant Shares: [] Issue Date: [], 2025 Initial Exercise Date: [], 2025 THIS PLACEMENT AGENT ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at |
|
| June 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| June 25, 2025 |
Filing Fee Table (filed herewith). Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Lifeward Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price (1)(2) Fee Rate Amount of Registration Fee Ca |
|
| June 25, 2025 |
Form of Pre-Funded Warrant (filed herewith). Exhibit 4.17 PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT LIFEWARD LTD. Warrant Shares: Initial Exercise Date: [], 2025 Issue Date: [], 2025 THIS PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or |
|
| June 25, 2025 |
Exhibit 10.30 Execution Version January 6, 2025 STRICTLY CONFIDENTIAL Lifeward Ltd. 200 Donald Lynch Blvd. Marlborough, MA 01752 Attn: Larry Jasinski, Chief Executive Officer Dear Mr. Jasinski: This letter agreement (this “Agreement”) constitutes the agreement between Lifeward Ltd. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”), that Wainwright shall serve as the exclusive underwrit |
|
| June 25, 2025 |
Form of Warrant (filed herewith). Exhibit 4.18 ORDINARY SHARE PURCHASE WARRANT LIFEWARD LTD. Warrant Shares: Issue Date: [], 2025 [Initial Exercise Date: , 2025]1 THIS ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the [Shareholde |
|
| June 25, 2025 |
Exhibit 10.31 Execution Version May 13, 2025 STRICTLY CONFIDENTIAL Lifeward Ltd. 200 Donald Lynch Blvd. Marlborough, MA 01752 Attn: Larry Jasinski, Chief Executive Officer Dear Mr. Jasinski: Reference is made to that certain engagement agreement (the “Engagement Agreement”), dated as of January 6, 2025, by and between Lifeward Ltd. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”). Def |
|
| June 25, 2025 |
As filed with the U.S. Securities and Exchange Commission on June 25, 2025. As filed with the U.S. Securities and Exchange Commission on June 25, 2025. Registration No. 333-288172 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Lifeward Ltd. (Exact name of registrant as specified in its charter) State of Israel 3842 Not Applicable (State or Other Jurisdiction of Inc |
|
| June 25, 2025 |
Form of Securities Purchase Agreement (filed herewith). Exhibit 10.29 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June [●], 2025, between Lifeward Ltd., a corporation organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subje |
|
| June 25, 2025 |
Form of Placement Agent Warrant (filed herewith). Exhibit 4.19 PLACEMENT AGENT ORDINARY SHARE PURCHASE WARRANT LIFEWARD LTD. Warrant Shares: Issue Date: [], 2025 [Initial Exercise Date: , 2025]1 THIS PLACEMENT AGENT ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any |
|
| June 20, 2025 |
Form of Securities Purchase Agreement (filed herewith). Exhibit 10.30 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June [●], 2025, between Lifeward Ltd., a corporation organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subje |
|
| June 20, 2025 |
As filed with the U.S. Securities and Exchange Commission on June 20, 2025. As filed with the U.S. Securities and Exchange Commission on June 20, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Lifeward Ltd. (Exact name of registrant as specified in its charter) State of Israel 3842 Not Applicable (State or Other Jurisdiction of Incorporation or (Primary St |
|
| June 20, 2025 |
Filing Fee Table (filed herewith). Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Lifeward Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price (1)(2) Fee Rate Amount of Registration Fee Ca |
|
| June 20, 2025 |
Form of Pre-Funded Warrant (filed herewith). Exhibit 4.17 PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT LIFEWARD LTD. Warrant Shares: Initial Exercise Date: [], 2025 Issue Date: [], 2025 THIS PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or |
|
| June 20, 2025 |
Employment Agreement, dated May 16, 2025, by and between Lifeward, Inc. and Mark Grant. Exhibit 10.29 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is dated as of May 16, 2025, by and between Lifeward, Inc., a Delaware corporation (the “Company”) (together with its present or future subsidiaries and affiliates, the “Group Companies”), with offices at 200 Donald Lynch Boulevard, Marlboro, MA 01752 and Mark Grant (the “Employee”) of Charlotte, North Carolina. WITNESS |
|
| June 20, 2025 |
Form of Placement Agent Warrant (filed herewith). Exhibit 4.19 PLACEMENT AGENT ORDINARY SHARE PURCHASE WARRANT LIFEWARD LTD. Warrant Shares: Issue Date: [], 2025 [Initial Exercise Date: , 2025]1 THIS PLACEMENT AGENT ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any |
|
| June 20, 2025 |
Form of Warrant (filed herewith). Exhibit 4.18 ORDINARY SHARE PURCHASE WARRANT LIFEWARD LTD. Warrant Shares: Issue Date: [], 2025 [Initial Exercise Date: , 2025]1 THIS ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the [Shareholde |
|
| June 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| June 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2025 Lifeward Ltd. (Exact Name of Registrant as Specified in its Charter) Israel 001-36612 Not Applicable (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| June 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2025 Lifeward Ltd. (Exact Name of Registrant as Specified in its Charter) Israel 001-36612 Not Applicable (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 28, 2025 |
Exhibit 1.01 Conflict Minerals Report of Lifeward Ltd. For the year ended December 31, 2024 Introduction This is the Conflict Minerals Report (the “CMR”) of Lifeward Ltd. (the “Company,” “we” or “us” or “our”) for calendar year 2024 in accordance with Rule 13p-1 (the “Rule”) under the Securities Exchange Act of 1934, as amended (the “1934 Act”). The Rule requires disclosure of certain information |
|
| May 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Lifeward Ltd. (Exact name of the registrant as specified in its charter) State of Israel (State or other jurisdiction of incorporation) 001-36612 (Commission file number) 200 Donald Lynch Blvd. Marlborough, MA (Address of principal executive offices) 01752 (Zip Code) Mike Lawless, Chief Fi |
|
| May 27, 2025 |
DRS 1 filename1.htm Confidential Treatment Requested Pursuant to 17 C.F.R. Section 200.83 As confidentially submitted to the U.S. Securities and Exchange Commission on May 27, 2025. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXC |
|
| May 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 Lifeward Ltd. (Exact Name of Registrant as Specified in its Charter) Israel 001-36612 Not Applicable (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 19, 2025 |
Exhibit 99.1 Lifeward Names Mark Grant as New CEO Industry veteran brings 30 years of commercial leadership experience MARLBOROUGH, MA, and YOKNEAM ILLIT, Israel, May 19, 2025 – Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that Mark Grant has b |
|
| May 15, 2025 |
Form of Indenture (filed herewith). Exhibit 4.19 Form of Indenture LIFEWARD LTD. and INDENTURE Dated as of , 20 TABLE OF CONTENTS ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.01 Definitions 1 Section 1.02 Other Definitions 4 Section 1.03 Incorporation by Reference of Trust Indenture Act 4 Section 1.04 Rules of Construction 5 ARTICLE II THE SECURITIES 4 Section 2.01 Issuable in Series 4 Section 2.02 Establishment |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36612 Lifeward Ltd. (Exact |
|
| May 15, 2025 |
Filing Fee Table (filed herewith). Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Lifeward Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee C |
|
| May 15, 2025 |
Exhibit 99.1 Lifeward Ltd. Reports First Quarter 2025 Financial Results U.S. pipeline of ReWalk opportunities continues to build with over 120 qualified leads in process Closure of AlterG sites and resulting consolidation of resources and reduced expenditures yields improved operating expense trend Second consecutive quarter of AlterG revenue growth over 15% reflecting continued sales momentum MAR |
|
| May 15, 2025 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 Lifeward Ltd. (Exact Name of Registrant as Specified in its Charter) Israel 001-36612 Not Applicable (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 15, 2025 |
As filed with the Securities and Exchange Commission on May 15, 2025 As filed with the Securities and Exchange Commission on May 15, 2025 Registration No. |
|
| April 15, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2025 Lifeward Ltd. (Exact Name of Registrant as Specified in its Charter) Israel 001-36612 Not Applicable (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| April 15, 2025 |
Exhibit 99.1 Lifeward Launches Sales of the ReWalk 7 Personal Exoskeleton in U.S. Market Seventh generation of industry-leading personal exoskeleton is now available nationwide for individuals with spinal cord injury New and improved features streamline user experience for greater control, engagement, and confidence during walking in everyday environments MARLBOROUGH, Mass. and YOKNEAM ILLIT, Isra |
|
| April 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2025 Lifeward Ltd. (Exact Name of Registrant as Specified in its Charter) Israel 001-36612 Not Applicable (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| March 7, 2025 |
Exhibit 19.1 LIFEWARD LTD. INSIDER TRADING POLICY This document sets forth the Insider Trading Policy (the “Policy”) of Lifeward Ltd. (“Lifeward”). The Policy establishes the policies and procedures that govern trading by Lifeward personnel in Lifeward securities and securities of any other company about which such personnel learns material, nonpublic information in the course of performing his or |
|
| March 7, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2025 Lifeward Ltd. (Exact Name of Registrant as Specified in its Charter) Israel 001-36612 Not Applicable (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| March 7, 2025 |
Exhibit 99.1 Lifeward Ltd. Reports Fourth Quarter and Full Year 2024 Financial Results Record quarterly and annual revenue of $7.5M and $25.7M, respectively Continued strong growth in U.S. pipeline of ReWalk opportunities with over 110 qualified leads in process Strategic shift towards profitability: 2025 Sustainable Growth Plan focuses on growth of core product lines with a streamlined cost struc |
|
| March 7, 2025 |
Exhibit 10.23 CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. MANUFACTURING SERVICES AGREEMENT THIS MANUFACTURING SERVICES AGREEMENT (this “Agreement”) is made on October 3, 2024 (the “Effective Date”), by and between Lifeward, Inc., a Delaware corporation having |
|
| March 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2025 Lifeward Ltd. (Exact Name of Registrant as Specified in its Charter) Israel 001-36612 Not Applicable (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| March 7, 2025 |
Filed Pursuant to Rule 424(b)(5) Registration No 333-263984 PROSPECTUS SUPPLEMENT (To Prospectus dated May 16, 2022) Up to $5,488,800 Ordinary Shares We have entered into an At The Market Offering Agreement (the “Sales Agreement”), dated March 7, 2025, with H. |
|
| March 7, 2025 |
Exhibit 10.22 AMENDMENT #1 TO EXECUTIVE EMPLOYMENT AGREEMENT This Amendment #1 to the Executive Employment Agreement (this “Amendment”) is made and entered into on September 23, 2020, by and between ReWalk Robotics Inc. (formerly Argo Medical Technologies Inc.),a Delaware corporation (the “Company”), and Larry Jasinski (the “Employee”). The Company and the Employee shall each be referred to as a “ |
|
| March 7, 2025 |
Exhibit 10.1 AT THE MARKET OFFERING AGREEMENT March 7, 2025 H.C. Wainwright & Co., LLC 430 Park Avenue, 3rd Floor New York, NY 10022 Ladies and Gentlemen: Lifeward Ltd., a corporation organized under the laws of the State of Israel (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms that follow, when used |
|
| March 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT OR SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36612 Lifeward Ltd. (Exact name |
|
| February 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2025 Lifeward Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 14, 2025 |
As filed with the Securities and Exchange Commission on February 14, 2025 As filed with the Securities and Exchange Commission on February 14, 2025 Registration No. |
|
| February 14, 2025 |
[Remainder of Page Intentionally Blank] February 14, 2025 VIA EDGAR Division of Corporation Finance Office of Industrial Applications and Services Securities and Exchange Commission 100 F Street, NE Washington, D. |
|
| February 11, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Lifeward Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee New |
|
| February 11, 2025 |
As filed with the Securities and Exchange Commission on February 11, 2025 As filed with the Securities and Exchange Commission on February 11, 2025 Registration No. |
|
| January 14, 2025 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. |
|
| January 13, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 Lifeward Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| January 13, 2025 |
Lifeward Cancels Its Extraordinary General Meeting of Shareholders Exhibit 99.1 Lifeward Cancels Its Extraordinary General Meeting of Shareholders MARLBOROUGH, MA, and YOKNEAM ILIT, Israel, January 13, 2025 – Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), today announced that it has cancelled its previously announced Extraordinary General Meeting of Shareholders that had been scheduled for January 13, 2025. The Board of Directors of Lifeward (the “Bo |
|
| January 8, 2025 |
Lifeward Ltd. 1,818,183 Ordinary Shares As filed pursuant to Rule 424(b)(5) Registration No. 333-263984 PROSPECTUS SUPPLEMENT (To Prospectus dated May 16, 2022) Lifeward Ltd. 1,818,183 Ordinary Shares We are offering 1,818,183 ordinary shares, par value NIS 1.75 per ordinary share, to certain institutional investors at an offering price of $2.75 per share. In a concurrent private placement, we are also selling to such purchasers warrant |
|
| January 8, 2025 |
Form of Securities Purchase Agreement. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 7, 2025, between Lifeward Ltd., a company organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject t |
|
| January 8, 2025 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 8, 2025 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 8, 2025 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 8, 2025 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2025 Lifeward Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) |
|
| January 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2025 Lifeward Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| January 8, 2025 |
Lifeward Announces $5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Exhibit 99.1 Lifeward Announces $5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules MARLBOROUGH, MA, and YOKNEAM ILIT, Israel, January 7, 2025 – Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life’s passions in the face o |
|
| December 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| November 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| November 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| November 12, 2024 |
Exhibit 3.1 THE ISRAELI COMPANIES LAW A COMPANY LIMITED BY SHARES SIXTH AMENDED AND RESTATED ARTICLES OF ASSOCIATION OF Lifeward Ltd. GENERAL PROVISIONS 1. Definitions a) In these Articles the following terms shall bear the meaning ascribed to them below: “Alternate Director” is defined in Article 41. “Annual General Meeting” shall have the meaning assigned to such term in the Companies Law. The “ |
|
| November 12, 2024 |
Exhibit 99.1 Lifeward Ltd. Reports Third Quarter 2024 Financial Results Second consecutive quarter of 20 ReWalk systems sold Robust growth in U.S. ReWalk pipeline of approximately 70 qualified leads for potential claim submission with Medicare and other U.S. payors MARLBOROUGH, MA, and YOKNEAM ILLIT, Israel, November 12, 2024 – Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36612 Lifeward Ltd. (E |
|
| November 12, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 Lifeward Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2024 Lifeward Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| September 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2024 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| August 15, 2024 |
Exhibit 99.1 Lifeward Reports Second Quarter 2024 Financial Results Record ReWalk revenue with 20 systems placed Q2’24 revenue of $6.7M up over 400% compared to $1.3M in Q2’23 Medicare claims for submissions from prior quarters beginning to be paid MARLBOROUGH, MA, and YOKNEAM ILLIT, Israel, August 15, 2024 – ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq: LFWD) (“Lifeward” or the “Company”), a glo |
|
| August 15, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2024 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36612 ReWalk Robotics Ltd. |
|
| August 14, 2024 |
Exhibit 10.1 EMPLOYMENT AND RELOCATION AGREEMENT This EMPLOYMENT AGREEMENT is dated as of July 17, 2024, by and between Lifeward, Inc., a Delaware corporation (the “Company”), with offices at 200 Donald Lynch Boulevard, Marlborough, MA 01752 and Almog Adar (the “Employee”) of Ein HaEmek, Israel. WITNESSETH: WHEREAS the Company desires to enter into employment with the Employee for the period provi |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| July 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| July 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| July 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2024 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 28, 2024 |
Exhibit 1.01 Conflict Minerals Report of ReWalk Robotics Ltd. For the year ended December 31, 2023 Introduction This is the Conflict Minerals Report (the “CMR”) of ReWalk Robotics Ltd. (the “Company,” “we” or “us” or “our”) for calendar year 2023 in accordance with Rule 13p-1 (the “Rule”) under the Securities Exchange Act of 1934, as amended (the “1934 Act”). The Rule requires disclosure of certai |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT ReWalk Robotics Ltd. (Exact name of the registrant as specified in its charter) State of Israel (State or other jurisdiction of incorporation) 001-36612 (Commission file number) 3 Hatnufa Street, Floor 6, Yokneam Ilit, Israel (Address of principal executive offices) 2069203 (Zip Code) Mike |
|
| May 15, 2024 |
Exhibit 99.1 Lifeward Reports First Quarter 2024 Financial Results Q1’24 revenue of $5.3M is up 340% vs. Q1’23 and at the midpoint of Lifeward’s guidance range Newly established Medicare payment for ReWalk Personal Exoskeleton favorably impacts Q1’24 results Medicare Administrative Contractors (“MACs”) approve 14 claims since fee schedule established MARLBOROUGH, MA, and YOKNEAM ILLIT, Israel, May |
|
| May 15, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36612 ReWalk Robotics Ltd. |
|
| May 15, 2024 |
Fifth Amended and Restated Articles of Association of the Company. Exhibit 3.1 THE ISRAELI COMPANIES LAW A COMPANY LIMITED BY SHARES FIFTH AMENDED AND RESTATED ARTICLES OF ASSOCIATION OF ReWalk Robotics Ltd. GENERAL PROVISIONS 1. Definitions a) In these Articles the following terms shall bear the meaning ascribed to them below: “Alternate Director” is defined in Article 41. “Annual General Meeting” shall have the meaning assigned to such term in the Companies Law |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT OR SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36612 ReWalk Robotics Ltd. (E |
|
| April 29, 2024 |
Fifth Amended and Restated Articles of Association of the Company.*** Exhibit 3.1 THE ISRAELI COMPANIES LAW A COMPANY LIMITED BY SHARES FIFTH AMENDED AND RESTATED ARTICLES OF ASSOCIATION OF ReWalk Robotics Ltd. GENERAL PROVISIONS 1. Definitions a) In these Articles the following terms shall bear the meaning ascribed to them below: “Alternate Director” is defined in Article 41. “Annual General Meeting” shall have the meaning assigned to such term in the Companies Law |
|
| April 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2024 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission F |
|
| April 19, 2024 |
Exhibit 99.1 Lifeward Announces the Appointment of Mike Swinford to its Board of Directors Experienced healthcare and rehabilitation technology professional brings more than 30 years of experience in commercialization and new business development MARLBOROUGH, MA, and YOKNEAM ILLIT, Israel, April 19, 2024 – ReWalk Robotics Ltd. (DBA Lifeward™) (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global |
|
| April 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2024 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| April 3, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2024 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| April 3, 2024 |
Exhibit 99.1 Investor Presentation April 2024 we are partners in energy storage Forward Looking Statements This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. All statements contained in this presentation oth |
|
| February 27, 2024 |
Exhibit 21.1 List of Subsidiaries of ReWalk Robotics Ltd. Name of Subsidiary Place of Incorporation Lifeward, Inc. Delaware, United States Lifeward CA, Inc. Delaware, United States Lifeward GmbH Germany |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT OR SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36612 ReWalk Robotics Ltd. (Exa |
|
| February 27, 2024 |
Exhibit 99.1 Lifeward Reports Fourth Quarter and Full Year 2023 Financial Results Highest quarterly and annual revenue in the history of Lifeward Commercial and operational integration complete; synergies expected to yield $3 million in annual net savings MARLBOROUGH, MA, and YOKNEAM ILLIT, Israel, February 27, 2024 – ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq: LFWD) (“Lifeward” or the “Company |
|
| February 27, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commissio |
|
| January 30, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2024 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 30, 2024 |
ReWalk Robotics Transforms Company Identity, Rebrands as Lifeward Exhibit 99.1 ReWalk Robotics Transforms Company Identity, Rebrands as Lifeward Lifeward brand reflects the Company’s commitment to pioneering innovative technology to empower the pursuit of life’s ambitions in the face of physical limitation or disability. The complete rebrand includes new name, stock ticker, logo, website launch, and corporate messaging. MARLBOROUGH, MA, BERLIN, Germany, and YOKN |
|
| December 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2023 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 14, 2023 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is dated as of August 11, 2023, by and between ReWalk Robotics, Inc., a Delaware corporation (the “Company”), with offices at 200 Donald Lynch Boulevard, Marlboro, MA 01752 and Charles Remsberg (the “Employee”) of 770 Luce Court, Mountain View, CA 94041. WITNESSETH: WHEREAS the Company desires to enter into employment wi |
|
| November 14, 2023 |
Exhibit 10.2 REWALK ROBOTICS LTD. 2014 INCENTIVE COMPENSATION PLAN Notice of Restricted Stock Unit Grant (Inducement Award) Participant: Company: [•] ReWalk Robotics Ltd. Notice: You have been granted the following Restricted Stock Units. This is an inducement grant, as described in NASDAQ Listing Rule 5635(c)(4). Accordingly, the Restricted Stock Units have been granted outside of the Plan. Howev |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commissio |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36612 ReWalk Robotics |
|
| November 14, 2023 |
Exhibit 99.1 ReWalk Robotics Reports Third Quarter 2023 Financial Results Record Quarterly Revenue of $4.4 Million Successful Completion of AlterG Acquisition and Significant Progress of Integration Major Advancement in Efforts to Attain Medicare Payment Coverage of Exoskeletons MARLBOROUGH, Mass., BERLIN, Germany and YOKNEAM ILLIT, Israel, November 14, 2023 - ReWalk Robotics Ltd. (Nasdaq: RWLK) ( |
|
| October 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2023 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorpo |
|
| October 27, 2023 |
ALTERG INC. FOR THE QUARTER ENDED JUNE 30,2023 TABLE OF CONTENTS Exhibit 99.2 ALTERG INC. FOR THE QUARTER ENDED JUNE 30,2023 TABLE OF CONTENTS Page No. PART I FINANCIAL INFORMATION 2 ITEM 1. FINANCIAL STATEMENTS (unaudited) 2 CONDENSED BALANCE SHEETS - JUNE 30, 2023 AND DECEMBER 31, 2022 2 CONDENSED STATEMENTS OF OPERATIONS - SIX MONTHS ENDED JUNE 30, 2023 AND 2022 4 CONDENSED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED SHARES, COMMON SHARES AND SHAREHOLDERS |
|
| October 27, 2023 |
ReWalk Robotics Ltd. Unaudited Pro Forma Condensed Combined Financial Information Exhibit 99.3 ReWalk Robotics Ltd. Unaudited Pro Forma Condensed Combined Financial Information Introduction On August 8, 2023, ReWalk Robotics Ltd. (the “Parent”, “Company”, "ReWalk") entered into an Agreement and Plan of Merger (the “Merger Agreement”) with AlterG Inc., a Delaware corporation ("AlterG”), and Atlas Merger Sub, Inc. (“Merger Sub”), a Delaware corporation and wholly owned subsidiary |
|
| October 27, 2023 |
Exhibit 99.1 ALTERG INC. FINANCIAL STATEMENTS FOR THE YEARS ENDED DECEMBER 31, 2022 AND 2021 U.S. DOLLARS IN THOUSANDS ALTERG INC. INDEX Page Report of Independent Auditors 3 Balance Sheets 4 Statements of Operations 5 Statements of changes in Redeemable Convertible Preferred Shares, Common Shares and Shareholders' Deficit 6 Statements of Cash Flows 7 Notes to Financial Statements 8 - 29 - - - - - |
|
| October 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2023 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission |
|
| October 13, 2023 |
ReWalk Robotics Investor Presentation October 2023 Confidential – ReWalk Robotics 2023 NASDAQ:RWLK Exhibit 99.1 ReWalk Robotics Investor Presentation October 2023 Confidential – ReWalk Robotics 2023 NASDAQ:RWLK Forward Looking Statements This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. All statements co |
|
| October 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 6, 2023 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission |
|
| September 28, 2023 |
RWLK / Rewalk Robotics Ltd / Lind Global Fund II LP Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) ReWalk Robotics Ltd. (Name of Issuer) Ordinary shares, par value NIS 0.25 (Title of Class of Securities) M8216Q200 (CUSIP Number) Christopher P. Davis Kleinberg, Kaplan, Wolff & Cohen, P.C. 500 Fifth Avenue New York, NY 10110 (212) 986-6000 (Name, Address |
|
| September 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2023 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commissi |
|
| September 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2023 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commissio |
|
| September 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Def |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36612 ReWalk Robotics Ltd. |
|
| August 11, 2023 |
Exhibit 99.1 ReWalk Robotics Announces Closing of Acquisition of AlterG Combined Company Expected to Expand Access for Patients to Innovative Rehabilitation Technologies for Use in Clinics and the Home Charles Remsberg Appointed Chief Sales Officer at ReWalk Robotics MARLBOROUGH, MA, BERLIN, Germany, and YOKNEAM ILLIT, Israel (August 11, 2023) - ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or “th |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2023 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 11, 2023 |
Exhibit 99.1 ReWalk Robotics Reports Second Quarter 2023 Financial Results Revenue in Line with Prior Financial Guidance Continued Progress with CMS in Establishment of Medicare Benefit Category for Exoskeletons Pending Acquisition of AlterG Expected to Contribute to ReWalk Financial Results Starting in Q3’23 MARLBOROUGH, Mass. BERLIN, Germany and YOKNEAM ILLIT, Israel, August 11, 2023 - ReWalk Ro |
|
| August 11, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2023 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 11, 2023 |
Exhibit 10.1 AMENDMENT #1 TO EMPLOYMENT AGREEMENT This Amendment #1 to the Employment Agreement (this “Amendment”) is made and entered into on May 4, 2023, by and between ReWalk Robotics Ltd., a company organized under the laws of the State of Israel (the “Company”), and Almog Adar (the “Employee”). The Company and the Employee shall each be referred to as a “Party” and shall together be referred |
|
| August 9, 2023 |
Exhibit 99.1 ReWalk Robotics to Acquire AlterG; Acquisition Builds Commercial Scale and Accelerates Path to Profitability Combined Company Expands Patient and Clinician Access to Innovative Rehabilitation Technologies for Home and Clinic Use Transaction Projected to Increase Revenue Growth and Improve Operating Margin, While Reducing Cash Burn Rate MARLBOROUGH, MA, BERLIN, Germany, and YOKNEAM ILL |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 9, 2023 |
Exhibit 2.1 Execution Version Agreement and Plan of Merger by and among ReWalk Robotics, Inc., Atlas Merger Sub, Inc., AlterG, Inc. and Shareholder Representative Services LLC, as the Securityholder Representative August 8, 2023 THIS IS A DRAFT AGREEMENT ONLY AND DELIVERY OR DISCUSSION OF THIS DRAFT AGREEMENT SHALL NOT BE CONSTRUED AS AN OFFER OR COMMITMENT WITH RESPECT TO THE PROPOSED TRANSACTION |
|
| August 9, 2023 |
Exhibit 99.2 Confidential – ReWalk Robotics 2023 ReWalk Robotics Acquisition of AlterG Conference Call and Webcast August 9, 2023 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| July 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| July 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2023 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 30, 2023 |
Exhibit 1.01 Conflict Minerals Report of ReWalk Robotics Ltd. For the year ended December 31, 2022 Introduction This is the Conflict Minerals Report (the “CMR”) of ReWalk Robotics Ltd. (the “Company,” “we” or “us” or “our”) for calendar year 2022 in accordance with Rule 13p-1 (the “Rule”) under the Securities Exchange Act of 1934, as amended (the “1934 Act”). The Rule requires disclosure of certai |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) State of Israel (State or other jurisdiction of incorporation or organization) 001-36612 (Commission file number) Not applicable (IRS Employer Identification No.) 3 Hatnufa Street, Floor 6, Yokneam Ilit, Israel (Ad |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 11, 2023 |
Exhibit 99.1 ReWalk Robotics Reports First Quarter 2023 Financial Results On-Track Start to Fiscal Year with Progress in Advancing Reimbursement Coverage for Medicare Beneficiaries MARLBOROUGH, Mass. BERLIN, Germany and YOKNEAM ILLIT, Israel, May 11, 2023 - ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”), a leading provider of innovative technologies that enable mobility and wellne |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36612 ReWalk Robotics Ltd. |
|
| May 1, 2023 |
Exhibit 10.25 AMENDMENT #1 TO EXECUTIVE EMPLOYMENT AGREEMENT This Amendment #1 to the Executive Employment Agreement (this “Amendment”) is made and entered into on September 23, 2020, by and between ReWalk Robotics Inc. (formerly Argo Medical Technologies Inc.), a Delaware corporation (the “Company”), and Larry Jasinski (the “Employee”). The Company and the Employee shall each be referred to as a |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36612 ReWalk Robotics Ltd. (E |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2023 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission F |
|
| April 28, 2023 |
Exhibit 99.1 ReWalk Robotics Investor Presentation April 2023 Confidential – ReWalk Robotics 2023 NASDAQ:RWLK Forward Looking Statements This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. All statements cont |
|
| April 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2023 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission F |
|
| March 9, 2023 |
RWLK / Rewalk Robotics Ltd / Lind Global Fund II LP Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) ReWalk Robotics Ltd. (Name of Issuer) Ordinary shares, par value NIS 0.25 (Title of Class of Securities) M8216Q200 (CUSIP Number) Christopher P. Davis Kleinberg, Kaplan, Wolff & Cohen, P.C. 500 Fifth Avenue New York, NY 10110 (212) 986-6000 (Name, Address |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2023 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commissio |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT OR SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36612 ReWalk Robotics Ltd. (Exa |
|
| February 23, 2023 |
Exhibit 99.1 ReWalk Robotics Reports Fourth Quarter and Full Year 2022 Financial Results Strong Conclusion to 2022 – Q4’22 Revenue Highest Since Start of COVID-19 Pandemic Record Quarterly MyoCycle Sales Supplement Improved Exoskeleton Revenue MARLBOROUGH, Mass. BERLIN, Germany and YOKNEAM ILIT, Israel, February 23, 2023 - ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”), a medical |
|
| February 22, 2023 |
RWLK / Rewalk Robotics Ltd / Lind Global Fund II LP Activist Investment . UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) ReWalk Robotics Ltd. (Name of Issuer) Ordinary shares, par value NIS 0.25 (Title of Class of Securities) M8216Q200 (CUSIP Number) Christopher P. Davis Kleinberg, Kaplan, Wolff & Cohen, P.C. 500 Fifth Avenue New York, NY 10110 (212) 986-6000 (Name, Addres |
|
| February 22, 2023 |
Exhibit 99.2 February 22, 2023 Jeffrey Dykan Independent Chairman of the Board ReWalk Robotics Limited 3 Hatnufa Street, Floor 6 Yokneam Ilit, Israel 2069203 To the Board of Directors of ReWalk Robotics Limited (the “Company”): As you are aware, The Lind Partners, LLC and its affiliates (“Lind”) is the largest shareholder and a passionate supporter of ReWalk, holding 9,362,017 shares for 15.1% in |
|
| February 13, 2023 |
RWLK / Rewalk Robotics Ltd / Lind Global Fund II LP - AMENDMENT NO. 2 Passive Investment SC 13G/A 1 sc13ga.htm AMENDMENT NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* ReWalk Robotics Ltd. (Name of Issuer) Ordinary shares, par value NIS 0.25 (Title of Class of Securities) M8216Q200 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the ap |
|
| February 13, 2023 |
EX-99.1 2 exhibit99-1.htm JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Ordinary shares, par value NIS 0.25, of ReWalk Robotics Ltd. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedul |
|
| December 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2022 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commissio |
|
| December 22, 2022 |
Exhibit 99.1 ReWalk Announces Extension of Share Repurchase Program Reflects Confidence in Long-Term Potential of ReWalk MARLBOROUGH, Mass., BERLIN, Germany, and YOKNEAM ILIT, Israel, December 22, 2022 (GLOBE NEWSWIRE) - ReWalk Robotics Ltd. (Nasdaq: RWLK) (the ?Company? or ?ReWalk?), a leading manufacturer of robotic medical technology for people with lower extremity disabilities, today announced |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36612 ReWalk Robotics |
|
| November 7, 2022 |
Exhibit 10.2 Employee RSU REWALK ROBOTICS LTD. 2014 INCENTIVE COMPENSATION PLAN Notice of Restricted Stock Unit Grant (Inducement Award) Participant: [?] Company: ReWalk Robotics Ltd. Notice: You have been granted the following Restricted Stock Units. This is an inducement grant, as described in NASDAQ Listing Rule 5635(c)(4). Accordingly, the Restricted Stock Units have been granted outside of th |
|
| November 7, 2022 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT is dated as of September 19, 2022, by and between ReWalk Robotics, Inc., a Delaware corporation (the "Company"), with offices at 200 Donald Lynch Boulevard, Marlboro, MA 01752 and Michael A. Lawless (the "Employee") of Medfield, MA. WITNESSETH: WHEREAS the Company desires to enter into employment with the Employee for the period provided |
|
| November 7, 2022 |
Exhibit 99.1 ReWalk Robotics Reports Third Quarter 2022 Financial Results ReWalk Has Submitted the First Case to Medicare Administrative Contractors (MACs) for Coverage and Reimbursement of the ReWalk Exoskeleton for Medicare Beneficiaries As of November 4th, ReWalk Has Repurchased $0.9 Million of Common Stock Since Initiation of Its Program German Federal Social Court Hearing on November 10th wit |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission |
|
| October 14, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2022 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission |
|
| September 28, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2022 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commissi |
|
| September 28, 2022 |
REWALK TAKES ANOTHER STEP TOWARD MEDICARE COVERAGE Exhibit 99.1 REWALK TAKES ANOTHER STEP TOWARD MEDICARE COVERAGE ? ReWalk to submit first cases for Medicare coverage through Medicare Administrative Contractors (MACs) ? Centers for Medicare and Medicaid Services (CMS) affirms that the MACs have discretion to cover and reimburse the ReWalk exoskeleton ? CMS also plans to further deliberate on a benefit category designation for the ReWalk exoskelet |
|
| September 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2022 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commissio |
|
| September 6, 2022 |
As filed with the Securities and Exchange Commission on September 6, 2022 As filed with the Securities and Exchange Commission on September 6, 2022 Registration No. |
|
| September 6, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) ReWalk Robotics Ltd. |
|
| August 9, 2022 |
Exhibit 99.1 ReWalk Robotics Reports Second Quarter 2022 Financial Results Highlights June 8th Milestone Participation at Biannual CMS HCPCS Public Meeting as Part of Efforts to Gain ?Artificial Legs? Benefit Category Classification as Prosthetic for ReWalk Device Has Submitted 510k Application for ReWalk Stairs and Curbs Functionality MARLBOROUGH, Mass. BERLIN, Germany and YOKNEAM ILIT, Israel, A |
|
| August 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2022 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36612 ReWalk Robotics Ltd. |
|
| August 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2022 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| July 21, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2022 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| July 21, 2022 |
Exhibit 99.1 REWALK ROBOTICS LTD. 3 Hatnufa Street, Floor 6 Yokneam Ilit 2069203, Israel ReWalk Receives Court Approval for Share Repurchase Program MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, July 21, 2022 (GLOBE NEWSWIRE) - ReWalk Robotics Ltd. (Nasdaq: RWLK) (the ?Company? or ?ReWalk?), a leading manufacturer of robotic medical technology for people with lower extremity disabilities |
|
| July 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defini |
|
| June 23, 2022 |
DEFA14A 1 zk2228049.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitt |
|
| June 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defini |
|
| June 10, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2022 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| June 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2022 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| June 10, 2022 |
Exhibit 99.1 REWALK ROBOTICS LTD. 3 Hatnufa Street, Floor 6 Yokneam Ilit 2069203, Israel REWALK PROVIDES NOTICE OF 2022 ANNUAL MEETING OF SHAREHOLDERS Annual Meeting Will be Held on July 27, 2022 MARLBOROUGH, Mass. BERLIN and YOKNEAM ILIT, Israel - (BUSINESS WIRE) - ReWalk Robotics Ltd. (Nasdaq: RWLK), (the ?Company? or ?ReWalk?), a leading manufacturer of robotic medical technology for people wit |
|
| June 2, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2022 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| June 2, 2022 |
ReWalk Robotics Announces Share Repurchase Program Exhibit 99.1 ReWalk Robotics Announces Share Repurchase Program MARLBOROUGH, Mass. BERLIN and YOKNEAM ILIT, Israel, June 2, 2022 (GLOBE NEWSWIRE) -ReWalk Robotics Ltd. (Nasdaq: RWLK) (?ReWalk? or the ?Company?), a leading manufacturer of robotic medical technology for people with lower extremity disabilities, today announced that its Board of Directors (the ?Board?) has approved a program to repur |
|
| May 26, 2022 |
Exhibit 1.01 Conflict Minerals Report of ReWalk Robotics Ltd. For the year ended December 31, 2021 Introduction This is the Conflict Minerals Report (the ?CMR?) of ReWalk Robotics Ltd. (the ?Company,? ?we? or ?us? or ?our?) for calendar year 2021 in accordance with Rule 13p-1 (the ?Rule?) under the Securities Exchange Act of 1934, as amended (the ?1934 Act?). The Rule requires disclosure of certai |
|
| May 26, 2022 |
SD 1 zk2227916.htm SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) State of Israel (State or other jurisdiction of incorporation or organization) 001-36612 (Commission file number) Not applicable (IRS Employer Identification No.) 3 Hatnufa Street, Floor 6, Yo |
|
| May 26, 2022 |
DEFA14A 1 a2227910.htm DEFA 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2022 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction o |
|
| May 26, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2022 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 26, 2022 |
ReWalk Robotics Files Revised Preliminary Proxy Statement and Issues Letter to Shareholders Exhibit 99.1 ReWalk Robotics Files Revised Preliminary Proxy Statement and Issues Letter to Shareholders Highlights the Company?s Recent Progress and Momentum Towards Value-Enhancing Commercialization and Reimbursement Notes that Current Board and Management Team Have the Right Skill Sets, Institutional Knowledge and Third-Party Relationships to Implement Reimbursement Coverage and Create Long-Ter |
|
| May 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi |
|
| May 19, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2022 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 19, 2022 |
DEFA14A 1 a2227871.htm DEFA 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2022 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction o |
|
| May 19, 2022 |
ReWalk Robotics Confirms Receipt of Director Candidate Nominations from Creative Value Capital Exhibit 99.1 ReWalk Robotics Confirms Receipt of Director Candidate Nominations from Creative Value Capital Shareholders Are Not Required to Take Action at This Time MARLBOROUGH, Mass. BERLIN and YOKNEAM ILIT, Israel, May 19, 2022 (GLOBE NEWSWIRE) -ReWalk Robotics Ltd. (Nasdaq: RWLK) (?ReWalk? or the ?Company?), a leading manufacturer of robotic medical technology for people with lower extremity d |
|
| May 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number: 001-36612 ? ReWalk Robotics Ltd |
|
| May 13, 2022 |
Separation Agreement, dated March 8, 2022, by and between the Company and Ori Gon. Exhibit 10.2 To: Ori Gon By hand delivery / e-mail Date: March 8, 2022 Dear Ori, Re: Termination of Employment ? ReWalk Robotics Ltd. (the ?Company?) Following your notice dated December 13, 2021, of resignation from your employment by ReWalk Robotics Ltd. (the ?Company?), we are writing to confirm our understanding: 1. As of March 12, 2022 (the ?Termination Date?), your employment with the Compan |
|
| May 13, 2022 |
ReWalk Robotics Ltd. And subsidiaries Exhibit 99.1 ReWalk Robotics Reports First Quarter 2022 Financial Results CMS Healthcare Common Procedure Coding System (HCPCS) Public Meeting Agenda includes the ReWalk Exoskeleton MARLBOROUGH, Mass. BERLIN, Germany and YOKNEAM ILIT, Israel, May 13, 2022 - ReWalk Robotics Ltd. (Nasdaq: RWLK) (?ReWalk? or the ?Company?) today announced its financial results for the three months ended March 31, 202 |
|
| May 13, 2022 |
Exhibit 10.1 Certain portions of this document have been omitted pursuant to Item 601(a)(6) of Regulation S-K and, where applicable, have been marked with ?[***]? to indicate where omissions have been made. EMPLOYMENT AGREEMENT THIS PERSONAL EMPLOYMENT AGREEMENT (the ?Agreement?) is made and entered into this 10 of December 2019 by and between ReWalk Robotics Ltd. (the ?Company?), and Almog Adar ( |
|
| May 13, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2022 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 11, 2022 |
[Remainder of Page Intentionally Blank] May 11, 2022 VIA EDGAR Division of Corporation Finance Office of Life Sciences Securities and Exchange Commission 100 F Street, NE Washington, D. |
|
| May 2, 2022 |
Power of Attorney for Joseph Turk. Exhibit 24.2 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENT: That the undersigned director of ReWalk Robotics Ltd. does hereby constitute and appoint Larry Jasinski the lawful attorney and agent with power and authority to do any and all acts and things and to execute any and all instruments which said attorney and agent determines may be necessary or advisable or required to enable ReWalk Ro |
|
| May 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36612 ? ReWalk Robotics Ltd. |
|
| April 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2022 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission F |
|
| March 30, 2022 |
As filed with the Securities and Exchange Commission on March 30, 2022 As filed with the Securities and Exchange Commission on March 30, 2022 Registration No. |
|
| March 30, 2022 |
Filing Fee Table (filed herewith). Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) ReWalk Robotics Ltd. |
|
| March 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2022 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission F |
|
| February 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commissio |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36612 ? ReWalk Robotics Ltd. (E |
|
| February 24, 2022 |
Exhibit 4.2 DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a description of the ordinary shares, par value NIS 0.25 per share, of ReWalk Robotics Ltd. (the ?Company,? ?we? or ?us?) registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?). This description is a summary an |
|
| February 24, 2022 |
ReWalk Robotics Reports Fourth Quarter and Year End 2021 Financial Results Exhibit 99.1 ReWalk Robotics Reports Fourth Quarter and Year End 2021 Financial Results MARLBOROUGH, Mass. BERLIN, Germany and YOKNEAM ILIT, Israel, February 24, 2022 - ReWalk Robotics Ltd. (Nasdaq: RWLK) (?ReWalk? or the ?Company?) today announced its financial results for the three and twelve-months ended December 31, 2021. Highlights of and subsequent to the fourth quarter and FY 2021 include: |
|
| February 15, 2022 |
RWLK / Rewalk Robotics Ltd / ARMISTICE CAPITAL, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 15, 2022 |
Exhibit A AGREEMENT The undersigned agree that this Amendment No. 1 to Schedule 13G dated February 14, 2022 relating to the Ordinary Shares, par value NIS 0.25, of ReWalk Robotics Ltd. shall be filed on behalf of the undersigned. Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd Managing Member /s/ Steven Boyd Steven Boyd |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* ReWalk Robotics Ltd. (Name of Issuer) Ordinary Shares, NIS 0.25 par value per share (Title of Class of Securities) M8216Q200 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| February 11, 2022 |
RWLK / Rewalk Robotics Ltd / Lind Global Fund II LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ReWalk Robotics Ltd. (Name of Issuer) Ordinary shares, par value NIS 0.25 (Title of Class of Securities) M8216Q200 (CUSIP Number) January 27, 2022 (Information also provided as of December 31, 2021) (Date of Event which Requires Filing of this Statement) |
|
| December 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2021 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commissio |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commissio |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number: 001-36612 ? ReWalk Robotics |
|
| November 10, 2021 |
ReWalk Robotics Ltd. And subsidiaries Exhibit 99.1 ReWalk Robotics Reports Third Quarter 2021 Financial Results MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, Nov 10, 2021 (GLOBE NEWSWIRE) - ReWalk Robotics Ltd. (Nasdaq: RWLK) (?ReWalk? or the ?Company?) today announced its financial results for the three and nine months ended September 30, 2021. Highlights of and subsequent to the third quarter of 2021 include: ? Total reven |
|
| November 10, 2021 |
Exhibit 10.3 EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT dated as of July 22, 2021, by and between ReWalk Robotics, Inc., a Delaware corporation (the "Company"), with offices at 200 Donald Lynch Boulevard, Marlboro, MA 01752 and Jeannine Lynch (the "Employee") of San Francisco, CA. WITNESSETH: WHEREAS the Company desires to enter into employment with the Employee for the period provided in this Agre |
|
| November 1, 2021 |
As filed pursuant to Rule 424(b)(3) Registration No. 333-260382 PROSPECTUS 8,967,570 Ordinary Shares Issuable upon Exercise of Outstanding Warrants To be sold by Selling Shareholders This prospectus relates to the resale by the selling shareholders named herein, from time to time, of up to 8,967,570 ordinary shares, par value NIS 0.25 per share (the ?Ordinary Shares?), issuable upon exercise of ou |
|
| October 27, 2021 |
[Remainder of Page Intentionally Blank] CORRESP 1 filename1.htm October 27, 2021 VIA EDGAR Division of Corporation Finance Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: ReWalk Robotics Ltd. Registration Statement on Form S-3 (File No. 333-260382) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, ReWalk Robotics Ltd. (the “Company”) hereby requests acceleration of th |
|
| October 20, 2021 |
As filed with the Securities and Exchange Commission on October 20, 2021 As filed with the Securities and Exchange Commission on October 20, 2021 Registration No. |
|
| October 18, 2021 |
Exhibit 10.1 Certain confidential information contained in this document, marked by brackets and asterisk, has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K, because it (i) is not material and (ii) would be competitively harmful if publicly disclosed. AMENDMENT NO. 4 TO RESEARCH COLLABORATION AGREEMENT This Amendment No. 4 to Research Collaboration Agreement (this ?Amendment?) is |
|
| October 18, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2021 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission |
|
| October 4, 2021 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Ordinary shares, par value NIS 0.25, of ReWalk Robotics Ltd. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G. October 4, 2021 LIND GLOBAL FUND II LP By: Lind Global Partners II LLC its Ge |
|
| October 4, 2021 |
RWLK / Rewalk Robotics Ltd / Lind Global Fund II LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ReWalk Robotics Ltd. (Name of Issuer) Ordinary shares, par value NIS 0.25 (Title of Class of Securities) M8216Q200 (CUSIP Number) September 29, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| October 4, 2021 |
Exhibit 99.2 Due to the relationships amongst them, all of the Reporting Persons hereunder may be deemed to constitute a ?group? with one another for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended. |
|
| September 29, 2021 |
Exhibit 4.3 FORM OF PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT REWALK ROBOTICS LTD. Warrant Shares: Issue Date: [], 2021 Initial Exercise Date: [], 2021 THIS PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at a |
|
| September 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2021 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commissi |
|
| September 29, 2021 |
EX-10.2 8 exhibit10-2.htm EXHIBIT 10.2 Exhibit 10.2 Certain confidential information contained in this document, marked by brackets and asterisk, has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K, because it (i) is not material and (ii) would be competitively harmful if publicly disclosed. Execution Version September 24, 2021 STRICTLY CONFIDENTIAL ReWalk Robotics Ltd. Hatnufa Stre |
|
| September 29, 2021 |
EX-4.1 2 exhibit4-1.htm EXHIBIT 4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXC |
|
| September 29, 2021 |
As filed pursuant to Rule 424(b)(5) Registration No. 333-231305 PROSPECTUS SUPPLEMENT (To Prospectus dated May 23, 2019) ReWalk Robotics Ltd. 15,403,014 Ordinary Shares 610,504 Pre-funded Warrants to purchase One Ordinary Share 610,504 Ordinary Shares Underlying the Pre-funded Warrants We are offering 15,403,014 ordinary shares, par value NIS 0.25 per ordinary share, to certain institutional inves |
|
| September 29, 2021 |
EX-10.1 7 exhibit10-1.htm EXHIBIT 10.1 Exhibit 10.1 FORM OF SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 27, 2021, between ReWalk Robotics Ltd., a company organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchase |
|
| September 29, 2021 |
ReWalk Robotics Announces $32.5 Million Registered Direct Offering Priced At Premium to Market EX-99.1 9 exhibit99-1.htm EXHIBIT 99.1 Exhibit 99.1 ReWalk Robotics Announces $32.5 Million Registered Direct Offering Priced At Premium to Market MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, Sept. 27, 2021 (GLOBE NEWSWIRE) - ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) today announced that it has entered into definitive agreements with several institutional investors |
|
| September 29, 2021 |
Exhibit 99.2 ReWalk Robotics Announces Closing of $32.5 Million Registered Direct Offering Priced At Premium to Market MARLBOROUGH, Mass., BERLIN, Germany and YOKNEAM ILIT, Israel, Sept. 29, 2021 - ReWalk Robotics Ltd. (Nasdaq: RWLK) (?ReWalk? or the ?Company?) today announced the closing of its previously announced registered direct offering, priced at-the-market under Nasdaq rules, for the sale |
